EMVision Medical

What EMVision Medical does

EMVision Medical Devices Ltd (ASX:EMV) is an Australian medical technology company developing portable electromagnetic brain scanners for rapid point-of-care stroke diagnosis and monitoring. The company operates two product lines built on the same proprietary electromagnetic imaging platform: the emu Brain Scanner, a trolley-mounted bedside device for use in intensive care units, stroke and neurology wards, and emergency departments; and the First Responder Brain Scanner, an ultra-lightweight (<25 lb) device designed for embedding in road and air ambulances. Core technology uses proprietary antenna arrays that transmit low-power, non-ionizing ultra-high frequency radio waves (500–2000 MHz, scan power below 10% of a typical cell phone) into the head, with sensors detecting dielectric-property contrast between haemorrhage, ischaemia, and healthy tissue. Image reconstruction and stroke type classification are powered by AI running on the NVIDIA Jetson edge AI platform, with NVIDIA DGX systems used for model development, and the underlying IP stems from over a decade of research at the University of Queensland under co-inventor and CSO Professor Stuart Crozier.

The company's business model is pre-commercial: both devices are under clinical investigation and are not yet available for sale. Revenue will ultimately be generated through hardware sales to hospitals, stroke centers, and emergency medical services once regulatory clearance is obtained, with the emu device currently progressing through a Pivotal Trial at seven world-class stroke hospitals (Royal Melbourne Hospital, UTHealth/Memorial Hermann-Texas Medical Center, Mt Sinai West, Memorial Hermann Memorial City) to support FDA De Novo clearance, while the First Responder device has completed a 17-participant, 15-air-transfer feasibility study with the Royal Flying Doctor Service.

The company was founded in 2017–2018, listed on the ASX in December 2018, is headquartered in Sydney, Australia, and operates with an 11–50 employee base. As of May 2026 the company held $18.4M in cash, having raised a US$10M strategic equity investment from Keysight Technologies in February 2024, a $12M capital raising in September 2025, and multiple Australian government grants including a $5M Industry Growth Program grant in mid-2025.

Name

EMVision Medical

Legal name

EMVision Medical Devices Ltd

Website

https://emvision.com.au

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

EMVision Medical Devices (ASX:EMV) is an Australian medical technology company developing portable electromagnetic brain scanners — the emu bedside device and a backpack-sized First Responder device — that use AI to rapidly classify stroke type at the point of care for hospitals, stroke centers, and emergency medical services.

Ownership category

akta.pro rank

Product category

Portable Brain Imaging Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Analog Front-End (AFE) ICs (Sensor/Medical/Industrial AFE) (HDAHAIAJ)

Keywords

• Portable brain imaging
• Stroke diagnosis devices
• Electromagnetic neuroimaging
• Point-of-care imaging
• Pre-hospital stroke detection

Headquarters

HQ city

Brisbane

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. emu Brain Scanner (In-Hospital Device): EMVision's primary product is the emu bedside brain scanner, a trolley-mounted device for use in intensive care units, stroke and neurology wards, and rural emergency departments. Revenue will be generated through device sales to hospitals and healthcare systems following FDA regulatory clearance.
2. First Responder Brain Scanner (Pre-Hospital Device): Portable, lightweight scanner designed for road and air ambulances. Revenue will be generated through sales to emergency medical services, air ambulance operators, and mobile stroke units. The company completed feasibility study with Royal Flying Doctor Service in 2026 and will progress to production-equivalent units for regulatory testing.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

EMVision develops portable electromagnetic brain scanners that deliver rapid, AI-powered stroke type classification at the point of care. The emu Brain Scanner is a bedside/trolley-mounted device for in-hospital use in ICUs, stroke wards, and emergency departments, while the First Responder Brain Scanner is an ultra-lightweight (<25 lb) backpack-sized device designed for pre-hospital deployment in road and air ambulances. Both devices use proprietary antenna arrays that transmit non-ionizing low-power electromagnetic waves, detect dielectric tissue contrasts, and apply AI to classify stroke type (ischaemic vs haemorrhagic) within minutes, without the need for CT infrastructure.

Product overview

EMVision Medical Devices is an Australian medical technology company developing a portfolio of portable brain scanners for stroke diagnosis. The core product portfolio consists of two distinct devices: (1) the emu™ Brain Scanner, a bedside electromagnetic imaging device for in-hospital use in ICUs, stroke wards, and emergency departments; and (2) the First Responder Brain Scanner, a lightweight portable device designed for pre-hospital use in ambulances and air medical services. Both products utilize the same underlying electromagnetic neuroimaging technology with AI-powered stroke type classification to distinguish between ischemic (clot) and hemorrhagic (bleed) stroke, enabling faster triage and treatment decisions. Neither device is currently available for commercial sale as both remain under clinical investigation and regulatory testing.

Differentiator

Problem solved

Functional benefit

Brands

• emu: Bedside electromagnetic brain scanner for point-of-care stroke diagnosis and monitoring in hospitals

Products and services

• emu Brain Scanner A portable, cost-effective, non-ionising and safe bedside electromagnetic brain scanner that rapidly produces quality images of biological tissue and uses AI-powered stroke type identification (ischaemic vs haemorrhagic). One headset fits all head sizes with simple pre-set positioning and push-to-scan operation. Targeted at intensive care units, stroke and neurology wards, emergency departments, and rural hospitals. Pivotal validation trial began in March 2025 at Royal Melbourne Hospital (Australia) and UTHealth/Memorial Hermann-Texas Medical Center (US). Currently under clinical investigation and not available for sale.
• First Responder Brain Scanner An ultra-lightweight portable brain scanner embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients regardless of location. Weighs less than 25 lb with expanded antenna coverage for full brain coverage in a single scan. Uses a miniaturised version of EMVision's electromagnetic imaging technology with AI-powered stroke type classification. Feasibility study completed with Royal Flying Doctor Service in 2026 across 17 participants during 15 air transfers; production-equivalent units progressing to regulatory testing. Currently under clinical investigation and not available for sale.

Quantifiable outcome

• 92% of patients felt calm during scans and 100% were comfortable with family presence during First Responder Brain Scanner aeromedical feasibility study
• +3 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and major.

• Royal Flying Doctor Service (RFDS)coreStrategic or Co-development Partner · 27 May 2026EMVision completed a feasibility study for its First Responder Brain Scanner with the Royal Flying Doctor Service, validating scan data quality and operator usability in aeromedical conditions across 17 participants during 15 air transfers. The study confirmed flight conditions did not materially impact scan quality. RFDS staff received preliminary training, and the company will progress to production-equivalent units for regulatory testing.
• Australian Stroke AlliancecoreStrategic or Co-development PartnerEMVision collaborated with the Australian Stroke Alliance and Royal Flying Doctor Service to test its First Responder Proof-of-Concept brain scanner in remote settings. RFDS staff conducted volunteer scans in remote locations, and the device demonstrated ability to withstand physical stress, environmental conditions and operational constraints unique to aeromedical retrieval. A grant-funded Regional Benefits Study is set for launch in H2 2026.
• NVIDIAcoreTechnology or IntegrationEMVision is an Inception member of NVIDIA's program for AI startups. The company's lightweight brain-scanning device is built using the NVIDIA Jetson edge AI platform and NVIDIA DGX systems, enabling AI-powered image reconstruction and stroke type classification at the point of care.
• University of QueenslandcoreTechnology or IntegrationEMVision's brain scanner is the product of over a decade of research and development at The University of Queensland. Co-inventor Professor Stuart Crozier, former Director of Biomedical Engineering at UQ, developed the underlying electromagnetic imaging technology. His MRI advancements licensed to GE Healthcare and Siemens Healthineers underpin 65%+ of MRI machines since 1997.
• Royal Melbourne HospitalmajorStrategic or Co-development PartnerRoyal Melbourne Hospital is the first Australian site for EMVision's pivotal validation trial of the emu bedside brain scanner for stroke diagnosis. The hospital serves as a key clinical site for generating evidence supporting FDA De Novo clearance.
• UTHealth Science Center at Houston / Memorial Hermann-Texas Medical CentermajorStrategic or Co-development PartnerUTHealth Science Center at Houston and Memorial Hermann-Texas Medical Center are the first US sites for EMVision's pivotal validation trial of the emu bedside brain scanner, generating clinical evidence for FDA regulatory submission.
• Mt Sinai West (Manhattan)majorStrategic or Co-development PartnerMt Sinai West in Manhattan has been activated for enrolment in EMVision's Pivotal Trial for the emu point-of-care brain scanner, joining the roster of seven world-class stroke hospitals recruiting under the trial.
• Commonwealth CRC-P Grant Program CollaboratorscoreStrategic or Co-development PartnerEMVision collaborates with Commonwealth CRC-P Grant Program partners for clinical research and product collaboration. Partners include organizations supporting clinical development, validation, non-dilutive funding, and technology collaboration.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Penumbra: Penumbra is a neurovascular device leader with the largest stroke thrombectomy franchise. It is a broad incumbent in the stroke care continuum that could either partner with or acquire portable imaging players like EMVision to integrate triage and intervention.
• GE HealthCare: GE HealthCare is a global incumbent in CT, MRI, and PET neuroimaging and has historically licensed Professor Crozier's MRI technology. It is the most likely strategic acquirer or OEM partner if EMVision's technology proves out at scale.
• Siemens Healthineers: Siemens Healthineers is a global MRI/CT incumbent and a co-licensee of Crozier-era MRI IP. Relevant as a strategic acquirer, channel partner, or direct competitor if it chooses to enter portable brain imaging.
• Philips Healthcare: Philips is a global imaging incumbent with a strong neurology/stroke portfolio (inc. rapid CT, interventional neuro). Relevant as a broad incumbent that could either develop competing portable imaging or partner with EMVision for distribution into its installed hospital base.
• Stryker Neurovascular: Stryker's Neurovascular division (acquired from Kalamazoo/Covidian) provides stroke intervention devices and is a deep incumbent across the stroke care continuum. Comparable as a potential acquirer or channel partner for portable pre-hospital imaging.

Emerging players

• Viz.ai: Viz.ai applies AI to existing CT imaging to triage suspected large vessel occlusion stroke and coordinate care via mobile. It is an adjacent competitor because it competes for the same pre-hospital/in-ED stroke workflow value pool, but uses software on existing imaging rather than a dedicated portable scanner.
• RapidAI: RapidAI provides AI-based stroke imaging analysis (Rapid ASPECTS, Rapid LVO) on CT/CTA/MRI. Like Viz.ai it does not sell a scanner, but competes for the workflow mindshare and reimbursement budget of stroke neurology departments that EMVision is also targeting.
• Cerca Magnetics: Cerca Magnetics has commercialized the first wearable magnetoencephalography (MEG) brain scanner (Optically Pumped Magnetometer-based). While focused on functional brain imaging rather than stroke triage, it is a peer in the niche of non-traditional, portable, non-ionizing brain imaging modalities.

Direct peers

• Medfield Diagnostics: Medfield Diagnostics (Sweden) is developing microwave-based portable brain scanners (Strokefinder) to differentiate ischemic and hemorrhagic stroke. It overlaps almost identically with EMVision on the underlying physics modality, target indication, and point-of-care use case.
• Hyperfine: Hyperfine is the most direct competitor — it has developed and FDA-cleared the Swoop portable point-of-care MRI brain scanner targeting ICU, ED, and stroke workflows. Both companies pursue portable bedside neuroimaging for rapid diagnosis without ionizing radiation, making them the closest head-to-head comparison for EMVision's emu device.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMVision Medical